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Abstract
Background: Modification of fatty acids (FA) composition in erythrocytes lipids as an early indicator of the
development of arterial hypertension (AH) and lipid disorders.
Methods: We included 34 patients with arterial hypertension and 11 healthy individuals. Each patient was
examined the lipid composition of serum. From erythrocytes by gas chromatography were identified fatty acids.
The quantitative composition of the erythrocyte lipids FA in patients with AH presented with saturated and
polyunsaturated monoenic acids with carbon chain lengths from C12 to C22.
Results: In all hypertensive patients is disturbed lipid FA composition of erythrocytes. The patients with a normal
level of serum lipids revealed deficiency of polyunsaturated acids n6-linoleic (18:2 n6), arachidonic (20:4 n6),
dokozatetraenic 14,4% (22:4 n6). The patients with dislipidemia installed more profound restructuring of the lipid
matrix of the membrane of erythrocytes. A decrease in polyunsaturated fatty acids family n3: dokozapentaenovoy
(22:5 n3), docosahexaenoic PUFA (22:6 n3), the total value of n3 PUFA in 1,3 times was revealed.
Conclusion: Thus, modification of erythrocyte FA are fairly subtle indicator of pathology of lipid metabolism, which
manifest themselves much earlier than changes in the lipoprotein of blood plasma.
Background
Modification of fatty acids composition of lipid matrix
of cell membrane has an important role in arterial
hypertension (AH) pathogenesis. It’sk n o w nt h a t
changes of the fatty acids (FA) composition, decreasing
of quantity of essential polyunsaturated fatty acids
(PUFA) may result in membrane microviscosity increas-
ing, proinflammatory eicosanoids synthesis activation
and increasing the smooth muscle cells in artery walls
sensivity to the influence of vasoconstrictors [1]. Cytosol
hypernatremia and hypercalcemia developed in FA
forming new ions channels of conductions assist to the
function disturbances of friable connective tissue, col-
lagen and elastin increasing both synthesis and secre-
tion. It probably leads to the thickening and decreasing
of arteries walls flexibility [2].
Researches devoted to the detailed studying of the
modification of FA in erythrocytes lipids in arterial
hypertension don’t create general image of typical
changes of FA composition in this category of patients
which connected to the variety of associated disorders
(obesity, resistance to the insulin, diabetes mellitus).
Arterial hypertension and dyslipidemia (DLP) - most
important and commonly present risk factors [3-7], with
prevalence of 50-80% [8-11] according to the different
authors. Among nontreated patients with AH the fre-
quency of DLP is 40%, on the other hand almost one
half of patients with increased level of total cholesterol
(TC) has systolic and diastolic hypertension [12-15].
The confirmation of adverse prognostic significance of
hypercholesterolemia was obtained by results of the
multicenter studies such as MRFIT (Multiple Risk Fac-
tor Intervention Trial) and Seven Countries Study.
According to these studies the growth of absolute and
relative characteristics of mortality from cardiovascular
disease in direct dependence of TC level [16-19] were
demonstrated on large populations.
* Correspondence: kanturovichi@yandex.ru
1Vladivostok Branch of the Far Eastern Center of Physiology and Pathology
of Respiration of SB RAMN - Institute of Medical Climatology and
Rehabilitative Treatment, Russia
Full list of author information is available at the end of the article
Novgorodtseva et al. Lipids in Health and Disease 2011, 10:18
http://www.lipidworld.com/content/10/1/18
© 2011 Novgorodtseva et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.That’s why the great interest is that immersed study-
ing of changing of spectrum of FA in erythrocytes lipids
in patients with arterial hypertension associated with
dyslipidemia.
Materials and methods
The research was performed according to the principles
of Helsinki Declaration (2000), with 34 patients with
diagnosed AH 1-2 stage, 11 male and 13 female (average
age - 49,21 ± 1,7). The control group consisted of 11
almost healthy persons.
The criteria for the inclusion into the study was diag-
nosed AH 1-2 stage. During diagnosis of AH practical
recommendations of European Society of Cardiology
(ESC) and European Society of Hypertension (ESH) [20]
were used.
The criteria for exclusion were AH with 3 stage, sec-
ondary hypertension, associated with the pathology of
urinary system (urolithiasis, acute and chronic pyelone-
phritis, polycystic kidney disease), endocrine system
(diabetes, hyperthyroidism, Cushing disease), as well as
concomitant diseases of the cardiovascular system (cor-
onary heart disease, stroke, myocardial infarction, car-
diac arhythmias).
The serum lipid spectrum was studied by the content
of cholesterol, triglycerides (TG), high density lipopro-
tein cholesterol (HDL) in serum with biochemical analy-
zer Photometer FM 750 (Germany), using sets of firm
“Olvex” (Russia). Results were expressed in mmol/liter.
The concentration of low density lipoproteins choles-
terol (LDL) and very low (VLDL) density were calcu-
lated by the formula: LDL = total cholesterol - (HDL +
VLDL), VLDL = TG/2,2, the results were expressed in
mmol/liter. Atherogenicity index (AI) was calculated by
the formula: AI = (TC - HDL)/HDL [21].
The extraction of lipids from erythrocytes was per-
formed by a modified method of Bligh and Dyer [22].
Gas-liquid chromatography of FA methyl ethers was
performed on gas-liquid chromatograph “Shimadzu-9A”
(Japan) with a flame ionization detector. Methyl ethers
of erythrocytes FA lipids were obtained by the method
of Carreau and Dyubak [23] and purified by thin-layer
chromatography. FA methyl ethers were analyzed by
capillary columns. The Chromaton N-AW-DMCS
0,100-0,125 was used as carrier, 5% Silar-5 CP, FFAP -
as the liquid phase. The evaporation temperature was
245°C. The separation temperature was 210°C. Helium
was the gas-carrier with linear velocity - 20 cm/sec. The
identification was performed using standard mixtures of
FA and the values of the equivalent chain length [24,25].
Quantitative calculations were performed using the stan-
dard software of data processing systems Chromatopak-
CR 3A. Results were expressed in relative % of total FA.
Unsaturation index (UsI) was calculated as the sum of
the products of double bonds in each of the FA with its
relative percentage.
Statistical data processing was performed using the
methods of descriptive statistics: the arithmetic mean,
the standard error of arithmetic mean (M ± m), the cri-
teria for significant differences (t) Student [26].
Results
Analysis of clinical and laboratory parameters allowed to
divide all patients with AH depending on the state of lipid
metabolism into 2 groups: 1 group - 16 patients with nor-
molipidemia, 2 group - 18 patients with dyslipidemia. The
criteria for dyslipidemia were levels of total cholesterol
(TC) >5.0 mmol/l, LDL cholesterol (LDL) >3.0 mmol/l, tri-
glycerides (TG) >1.77 mmol/l, high density lipoprotein
cholesterol (CH HDL) <1.0 mmol/l, atherogenic index (AI)
>3.5 a.u. [20]. Table 1 demonstrates the lipidogramm of
the observed persons. Level of serum lipids in patients in 1
group was normal. Patients in 2 groups have an increased
concentration of total cholesterol, TG, LDL, VLDL, and
IA, associated with the reduced level of HDL (Table 1).
The quantitative composition of the erythrocyte lipids
FA in patients with AH presented with saturated and
polyunsaturated monoenic acids with carbon chain
lengths from C12 to C22 (Table 1). The table doesn’t
contain some minor components of the FA which con-
tent does not exceed 0,1%. As follows from Table 2, the
FA composition in patients with AH without DLP
demonstrated increased proportion of saturated and
monoenic FA and reducing of polyenic FA.
There was a substantial increased level of margarinic
(17:0) to 60%, stearic (18:0) to 46.3%, eykozanoic (20:0)
to 72.2%, oleic (18:1 n9) to 12% and appearance of gep-
tadekamonoenic (17:1 n9) FA.
Such changes in monoenic acids composition make
the membrane more susceptible to oxidation while oleic
acid, being active endogenous invader of the active oxy-
gen forms, becomes a source of cytotoxic products of
lipid peroxidation, initiates the processes of membrane
destruction [1]. The reduction of the proportion of fatty
acids family n6 - linoleic (18:2 n6), arachidonic (20:4
n6), dokozatetraenic 14,4% (22:4 n6) was set, which
naturally resulted in the decrease in the total index of
unsaturated FA n6. Changes in the quantity of PUFA n3
was not revealed. Unsaturation index decreased due to
the lack of polyene n6.
An increased level of Mead acid 20:3 n9 to 79% was
revealed, which compensatory synthesis occurs in case
of deficit of the polyunsaturated acids family n6 and n3.
The increase of the proportion of Mead acid and
marked increasing of the level of oleic acid (18:1 n9)
declare active synthesis of substrates for the formation
of prostacyclines and thromboxanes, which have vaso-
constrictor properties [2,27].
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Page 2 of 5Table 1 Clinical and biochemical characteristics of patients with arterial hypertension, M ± m
Parameters Control group, n = 11 Patients with AH, n = 24
1 group (without DLP), n = 16 2 group (with DLP), n = 18
Systolic arterial pressure, mmHg. 105 ± 2 ***141 ± 2 ***141 ± 1
Diastolic arterial pressure, mmHg 65 ± 2 ***87 ± 1 ***88 ± 1
TC, mmol/l 4,44 ± 0,21 4,33 ± 0,06 **5,16 ± 0,13***
ТG, mmol/l 0,68 ± 0,07 **0,92 ± 0,04 ***1,79 ± 0,14***
HDL, mmol/l 1,41 ± 0,11 1,29 ± 0,02 ***0,97 ± 0,05***
LDL, mmol/l 2,72 ± 0,22 2,63 ± 0,06 ***4,00 ± 0,06***
VLDL, mmol/l 0,31 ± 0,03 *0,4 ± 0,01 ***0,65 ± 0,01***
AI, a.u. 2,27 ± 0,05 2,45 ± 0,08 ***4,35 ± 0,09***
Note: tabl. 1, 2 (*) - Statistically significant differences linked to the control group are on the left, - for the 1group are on the right: * - p < 0.05, ** - p < 0.01,
*** - p < 0,001.
Table 2 The content of FA in erythrocyte lipids in patients with AH, % of total FA sum M ± m
Fatty acids Control group, n = 11 Patients with AH, n = 34
1 group (without DLP), n = 16 1 group (with DLP), n = 16
14:0 0,65 ± 0,04 0,76 ± 0,06 ***0,41 ± 0,04***
15:0 0,28 ± 0,02 0,28 ± 0,02 *0,41 ± 0,05*
16:0 23,37 ± 0,32 22,70 ± 0,72 ***25,90 ± 0,42***
16:1n7 0,80 ± 0,03 ***0,5 ± 0,05 0,85 ± 0,09**
17:0 0,45 ± 0,04 ***0,72 ± 0,02 0,42 ± 0,01***
17:1n9 trace 0,20 ± 0,01 trace
18:0 17,23 ± 0,29 ***25,2 ± 0,18 17,03 ± 0,39***
18:1n9 13,25 ± 0,55 *14,85 ± 0,48 **15,02 ± 0,32**
18:1n7 1,38 ± 0,10 1,40 ± 0,02 1,60 ± 0,06**
18:2n6 13,74 ± 0,53 **11,60 ± 0,45 14,5 ± 0,2***
18:3n6 trace 1,28 ± 0,16 2,10 ± 0,54
18:4n3 trace 0,27 ± 0,01 trace
20:0 0,18 ± 0,02 ***0,31 ± 0,02 trace
20:1 0,28 ± 0,04 ***0,40 ± 0,01 trace
20:2n6 0,28 ± 0,02 0,34 ± 0,03 0,25 ± 0,02*
20:3n6 1,16 ± 0,05 1,10 ± 0,06 *1,34 ± 0,05**
20:3n9 0,48 ± 0,05 ***0,86 ± 0,06 ***0,88 ± 0,18
20:4n6 11,13 ± 0,24 ***10,5 ± 0,2 ***13,18 ± 0,18***
20:5n3 1,08 ± 0,11 1,16 ± 0,04 1,32 ± 0,10
22:4n6 2,15 ± 0,11 *1,84 ± 0,10 1,89 ± 0,13
22:5n6 0,2 ± 0,01 0,28 ± 0,01 trace
22:5n3 2,42 ± 0,16 2,22 ± 0,17 **1,81 ± 0,08*
22:6n3 5,8 ± 0,3 6,48 ± 0,35 **4,18 ± 0,40***
Sum 20-22n6 16,35 ± 0,52 15,30 ± 0,42 **14,38 ± 0,41
Sum 20-22n3 9,2 ± 0,3 9,6 ± 0,8 *7,70 ± 0,55*
20-22n3/20-22n6 0,58 ± 0,03 0,65 ± 0,05 0,50 ± 0,03*
Sum n6 30,1 ± 0,6 **27,01 ± 0,66 30,2 ± 0,4***
Sum n3 9,98 ± 0,78 10,0 ± 0,5 *7,5 ± 0,7**
n3/n6 0,31 ± 0,01 **0,37 ± 0,02 *0,26 ± 0,02**
22:6n3/22:5n3 2,4 ± 0,1 ***2,95 ± 0,12 2,26 ± 0,15***
20:4n6/22:6n3 2,11 ± 0,12 1,83 ± 0,12 *2,53 ± 0,13***
20:4n6/20:3n6 10,41 ± 0,40 10,72 ± 0,55 ***8,54 ± 0,31***
20:4n6/20:5n3 13,01 ± 0,99 **9,25 ± 0,52 ***8,01 ± 0,42
Unsaturation index 155,98 ± 1,33 **141,32 ± 4,38 157,9 ± 1,9**
Note: tabl. (*) - Statistically significant differences linked to the control group are on the left, - for the 1 group are on the right: * - p < 0.05, ** - p < 0.01,
*** - p < 0,001.
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metabolic disturbances in the transformations. Reduc-
tion ratio 20:4 n6/20: 5n3 detected in 1group patients
reflected the disturbance of FA synthesis - the forerun-
ner of eicosanoics of the different series. This state of
FA metabolism can lead to increased production of
oksilipins 2nd and 4th series demonstrating vasocon-
strictor, aggregation properties [1,28].
Comparative analysis of parameters between the
groups revealed some differences in changes of single
acids in patients with DLP. Most pronounced changes
in quantitative amount of saturated FA were established.
An accumulation of pentadekanoic (15:0) and palmitic
(16:0) acids were revealed. As in 1group, patients with
AH associated with dyslipidemia have a high content of
oleic acid and Mead acid.
Changes in PUFA composition are more pronounced,
especially with acids n3 structure. PUFA family n3defi-
ciency was confirmed with significant decrease of the
proportion of dokozapentaenoic (22:5 n3) and docosa-
hexaenoic PUFA (22:6 n3). There was a reduction of the
total value of n3 PUFA in patients with DLP in 1.3
times in comparison with 1 group.
A distinctive parameter of patients with AH associated
with DLP was rising of forerunner of eicosanoids with
vasoconstrictor effects - arachidonic acid (20:4 n6) to
26%. This is a sign of polyunsaturated acids n3 lack.
The imbalance in the composition of PUFA n3 and n6
is reflected in the decreasing ratio n3/n6. The 2 group
patients have the accumulation of saturated and polyun-
saturated n6 FA with deficit of PUFA n3 in the cyto-
membrane which indicates on the decreasing of the
fluidity of cell lipid bilayer, an activity of membrane
bound enzymes and inhibition of binding the ligands
with the receptor [1,27,29].
In respect that one of the reasons for modification of
the FA is a disturbance of its metabolism, their rates of
the transformations were analyzed. The analysis of para-
meters of the FA metabolic enzymes activity revealed
the reduction of the ratio 20:4 n6/20: 3n6, which indi-
cating the inhibition of eicosatrienoic acid metabolism.
Discovered changes in the ratio 20:4 n6/20: 5n3 and
20:4 n6/22: 6n3 involve an imbalance in eicosanoids
cycle in the direction of increasing the oksilipins synth-
esis with marked vasoconstrictor (thromboxane A2) and
proinflammatory (leukotriene B4) properties [1,27].
The results indicate a disturbance of the FA erythro-
c y t e sl i p i d si np a t i e n t sw i t hA Hr e g a r d l e s st ot h ep r e -
sence or absence of hyperlipidemia. A characteristic
feature of the modification of erythrocytes lipids FA com-
position in patients with normolipidemia is increased
proportion of margarinic, stearic, eicosanoic saturated
FA, Mead acid with low values for the polyunsaturated
acids n6 - linoleic and arachidonic.
It is known that the development of hypercholestero-
lemia preceded by blockade of cells active absorption of
essential polyunsaturated FA [1,2,27]. An indicator of
pathology of the active ligand-receptor transport of FA
is PUFA n3 and n6 deficiency. PUFA deficit modifies
the fluidity of annular phospholipids in the cells plas-
matic membrane, contributes to the dysfunction of the
bilayer integral proteins (ion pumps, receptors, transport
and signaling systems), which, being in an anhydrous
environment, change their conformation and function.
At the same time with developing the blockade of
income polyenic acids into the cell and changes in
receptor system, active transport into the cell of satu-
rated FA of VLDL breaks down by apoE/V-100 endocy-
tosis. The consequence of this process is compensatory
activation of adipocytes triglyceride hydrolysis and
increased elimination of saturated FA into the blood
flow. In this way conditions for the TG increasing in the
blood and the development of hypertriglyceridemia are
created. Therefore pathological changes in the composi-
tion of membrane lipids arising by the reason of the
breach of FA active transport leading to the formation
of AH and also become inevitable independent factors
for development of hyperlipidemia, which was con-
firmed by our studies [1,30].
It was shown that patients with AH associated with
hypercholesterolemia and hypertriglyceridemia revealed
a deeper restructuring of the erythrocytes membrane
lipid matrix. The increased proportion of the pentade-
kanoic, palmitic and arachidonic acid were demon-
strated. A distinctive feature of the modification of
erythrocytes lipids FA in patients with AH associated
with DLP was deficiency of PUFA n3. The observed
prevalence of saturated FA proportion in the erythro-
cytes with simultaneous lack of polyunsaturated acids
may be the evidence of transport pathology with a pre-
dominance of cells passive FA absorption. The integral
parameters of the cells impaired absorption both of
saturated FA and PUFA are low levels of HDL and
high levels of TG and cholesterol in the blood serum
[1,2,27]. Cells endogenous deficiency of n3 PUFA leads
to the changes of the plasmatic membranes physico-
chemical properties, activation of eicosanoids synthesis
with proinflammatory and vasoconstriction activity, the
formation of systemic inflammatory syndrome and
conditions for the atherogenesis [1].
Thus, structural and functional changes in erythrocyte
membranes in hypertension developed as a part of the
common systemic disorders of lipid metabolism. Defects
of receptor-mediated mechanism for the FA capture
induce the formation of AH. The increase in the disor-
ganization of the lipid components of the cell membrane
causes the development of hyperlipidemia and progres-
sion of hypertension. Modification of erythrocyte FA is
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manifested much earlier than lipoproteins changes in
the blood plasma. These findings clearly demonstrate
the important role of fatty acids in the pathogenesis of
cardiovascular diseases.
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